|
Press Releases |
|
|
|
Saturday, April 29, 2017 |
|
Nanobiotix: 2016 Annual Results |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2016. more info >> |
|
Tuesday, April 4, 2017 |
|
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the expansion and acceleration of its clinical development activities. more info >> |
|
Friday, March 24, 2017 |
|
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results (Act.In.Sarc) of NBTXR3 in soft tissue sarcoma. more info >> |
|
Tuesday, March 7, 2017 |
|
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017 |
NANOBIOTIX today announced the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in combination with chemotherapy, in both in vitro and in vivo studies. more info >> |
|
Tuesday, February 7, 2017 |
|
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO). more info >> |
|
Wednesday, February 1, 2017 |
|
NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides its activities and achievements during 2016 and an overview of anticipated 2017 milestones. more info >> |
|
Thursday, December 15, 2016 |
|
Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial |
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces a positive readout of initial data on the safety and feasibility from the first patients treated in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and metastatic tumors. more info >> |
|
Tuesday, November 29, 2016 |
|
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides an update on the global development of its lead product, NBTXR3, across all indications. more info >> |
|
Monday, November 14, 2016 |
|
Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells. more info >> |
|
Monday, November 7, 2016 |
|
Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. The trial is evaluating the optimal dose, safety and preliminary efficacy of Nanobiotix's lead product. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
亨利加集團舉辦更名誌慶暨香港交易所中午開市儀式
Dec 27, 2024 22:42 HKT/SGT
|
|
|
吳佩慈男友紀曉波發聲明 否認參與緬甸「恒升園區」
Dec 27, 2024 22:39 HKT/SGT
|
|
|
The Bilingual Book Company Launches New, Innovative Bilingual Audiobook App
Dec 27, 2024 22:30 HKT/SGT
|
|
|
Nakornthon Hospital PCL (SET: NKT) in First Trading Day on SET
Dec 27, 2024 18:53 HKT/SGT
|
|
|
Annual Surge of 37% in Legal and Compliance Job Roles while overall hiring drops 6% in Singapore: foundit Insights Tracker
Dec 27, 2024 15:20 HKT/SGT
|
|
|
Gruelling Challenge Awaits TGR In Saudi Arabia
Dec 27, 2024 15:20 JST
|
|
|
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
|
|
|
MHI Included in "World Index" of Dow Jones Sustainability Index for Second Consecutive Year
Dec 27, 2024 9:36 JST
|
|
|
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy
Dec 27, 2024 07:00: JST
|
|
|
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy
Dec 27, 2024 06:00 HKT/SGT
|
|
|
錨定高質量可持續增長路線 順豐控股構築長期主義價值底色
Dec 26, 2024 22:52 HKT/SGT
|
|
|
锚定高质量可持续增长路线 顺丰控股构筑长期主义价值底色
Dec 26, 2024 22:38 HKT/SGT
|
|
|
三菱重工、ESG投資指標「Dow Jones Sustainability Index(DJSI)」における「World Index」の構成銘柄に2年連続で選定
Dec 26, 2024 18:00: JST
|
|
|
TOYOTA GAZOO Racing to Exhibit at Tokyo Auto Salon 2025
Dec 26, 2024 17:11 JST
|
|
|
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
|
|
|
|
More News >> |
|
|
|
|
|